MRI-assessed atrophy subtypes in Alzheimer’s disease and the cognitive reserve hypothesis

Karin Persson1,2,3,*, Rannveig Sakshaug Eldholm4, Maria Lage Barca1,2, Lena Cavallin5,6, Daniel Ferreira7, Anne-Brita Knapskog3, Geir Selbæk1,8,9, Anne Brækhus1,2,3,10, Ingvild Saltvedt4,11, Eric Westman7, Knut Engedal1,2

1 Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway, 2 Department of Geriatric medicine, Oslo University Hospital, Ullevaal, Nøtterøy, Oslo, Norway, 3 Department of Geriatric Medicine, The memory clinic, Oslo University Hospital, Ullevaal, Nøtterøy, Oslo, Norway, 4 Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 5 Department of Clinical Science, Intervention, and Technology, Division of Medical Imaging and Technology, Karolinska Institute, Stockholm, Sweden, 6 Department of Radiology, Karolinska University Hospital, Stockholm, Sweden, 7 Division of Clinical Geriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, 8 Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway, 9 Institute of Health and Society, University of Oslo, Oslo, Norway, 10 Department of Neurology, Oslo University Hospital, Ullevaal, Nøtterøy, Oslo, Norway, 11 Department of Geriatrics, St Olav Hospital, University Hospital of Trondheim, Trondheim, Norway

* Karin.persson@aldringogelse.no

Abstract

Background/Aims

MRI assessment of the brain has demonstrated four different patterns of atrophy in patients with Alzheimer’s disease dementia (AD): typical AD, limbic-predominant AD, hippocampal-sparing AD, and a subtype with minimal atrophy, previously referred to as no-atrophy AD. The aim of the present study was to identify and describe the differences between these four AD subtypes in a longitudinal memory-clinic study.

Methods

MRI assessment of the brain was segmented into atrophy subtypes based on the presence of atrophy in the medial temporal lobes, the frontal regions, and the posterior regions. These subtypes were further characterized by demographic data, neuropsychological measures, cerebrospinal-fluid biomarkers, and progression rate of dementia at two-year follow-up were compared between the groups.

Results

Typical AD was found in 59 patients (48%); 29 (24%) patients had limbic-predominant AD; 19 (15%) had hippocampal-sparing AD; and 16 (13%) belonged to the group with minimal atrophy. No differences were found regarding cognitive test results or progression rates between the different subtypes. Using adjusted logistic regression analysis, we found that the patients in the minimal-atrophy group were less educated, had a lower baseline CDR sum of boxes score, and had higher levels of amyloid β in the cerebrospinal fluid.
Conclusion

Previous results concerning the prevalence and the similar phenotypic expressions of the four AD subtypes were confirmed. The main finding was that patients with minimal atrophy as assessed by MRI had less education than the other AD subtypes and that this could support the cognitive reserve hypothesis and, at least in part, explain the lower degree of atrophy in this group. Patients with less formal education might present with clinically typical AD symptoms before they have positive biomarkers of AD and this finding might challenge suggested biomarker-based criteria for AD.

Introduction

The typical symptomatology of Alzheimer’s disease (AD) includes the impairment of episodic memory [1], but atypical presentations with other debut symptoms such as language, visuospatial, or behavior predominant dysfunction have been found to exist in approximately 6% to 30% of AD patients [2, 3]. Similarly, the typical pathological pattern of AD includes the accumulation of amyloid plaques and neurofibrillary tangles distributed in a characteristic way [4, 5], but in approximately one of four patients, the typical medial temporal lobe and associative cortex distribution of neurofibrillary tangles is lacking [6]. Instead, limbic-predominant or hippocampal-sparing atypical presentations have been identified [6].

It has been demonstrated that volumetric MRI measurements of regional brain atrophy correlate with the distribution and degree of neurofibrillary tangle pathology [7, 8], making MRI a potential surrogate marker of regional tangle distribution. Furthermore, a correlation between the previously described neuropathologically defined subtypes and volumetric MRI has been confirmed [9].

Several recent studies have used MRI measures as in vivo markers to explore the aforementioned tangle/atrophy-based AD subtypes [10–12]. Byun et al. used voxel-based morphometry (VBM) and Ferreira et al. used visually assessed MRI to categorize highly selected, longitudinally assessed patients from the ADNI cohort into subgroups [10, 11, 13]. These studies identified the same three AD subtypes that had been found in previous neuropathological studies: typical AD, limbic-predominant AD, and hippocampal-sparing AD. In addition, a fourth group lacking evident atrophy in both medial temporal and associative cortex areas, previously called no-atrophy AD, was reported. As it is difficult to completely rule out some degree of atrophy, a more suitable term for this entity may be minimal-atrophy AD, and this term is used for this subtype in the current study. This subtype attracts special interest, as one of the major hallmarks of AD, i.e., atrophy, is lacking or at least minimal, thereby questioning the diagnostic value of MRI-evaluated atrophy in AD, especially as a mandatory diagnostic criterion.

Thus, the aim of the present study was to explore whether we could find the same four subtypes in a sample of memory-clinic patients who have been followed up for two years, as have previously been found in highly selected ADNI patients. Secondly, we wanted to describe differences between the subtypes with regard to demographic data, neuropsychological measurements, neuropsychiatric symptomatology, and cerebrospinal fluid biomarkers, with a special emphasis on the minimal-atrophy group. Thirdly, we wanted to examine the progression rate of the subtypes, as this has not been done in a clinical, naturalistic AD cohort before.
Materials and methods

Participants

The patients were recruited from a larger study for which the inclusion process has been described thoroughly in a previous paper [14]. For the present study, only patients with a baseline diagnosis of AD with a mild degree of dementia were included (n = 155). Of these, 123 patients had been assessed with MRI of the brain within six months prior to or after the clinical examination at baseline (in 91% of the patients, less than four months between clinical examination and MRI) and had been followed up after 24 months on average (range 17–34 months).

Diagnoses

Two of the authors (MLB and KP) had conducted an interrater reliability analysis of 51 patients including eight different diagnoses, demonstrating very good interrater agreement for early- and late-onset AD (kappa 0.73 and 0.85 respectively) [14, 15]. Therefore, patients with AD were diagnosed by one of these authors alone or by two other authors in consensus (RSE and IS), according to the ICD-10 and NINCDS-ADRDA criteria based on all available clinical information, without knowledge of the results of the MRI visual rating scales. Patients with mixed AD/vascular disease (n = 3) were regarded as having AD. All patients had mild dementia according to the ICD-10 and CDR score of 0.5 or 1.0. Although clinical MRI reports and the results of the CSF biomarkers were available, this information was included only in the diagnostic workup according to the diagnostic criteria [16, 17]. APOE-ε4 status was not available during the diagnostic workup.

At follow-up, the patients were diagnosed again by the same authors. All patients except for two retained their baseline diagnosis (MCI due to AD at follow-up, one with limbic-predominant and one with typical AD pattern).

Clinical assessment

All patients were clinically assessed with a standardized examination protocol [18]. For the present study, the following cognitive measures were used to characterize the patients: the Mini-Mental State Examination–Norwegian Revised Version (MMSE-NR), a measure of global cognitive function that can be scored from zero to 30, with a higher score denoting better cognitive functioning [19, 20]; the clock-drawing test, measuring visuomotor and executive functions on a scale from zero to 5, with higher scores indicating better functioning [21]; the Trail Making Test A and B to assess psychomotor speed and executive function, measured by the number of seconds used to complete the test, with a longer time indicating more impaired functioning [22] (the result was dichotomized to 1 if the patient performed the test better than 180/360 seconds (test A/test B), and 0 for results above 180/360 seconds, or if the patient was too cognitively impaired to perform the test); the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 10-word delayed recall test with scores from zero to 10, with a higher score denoting better delayed recall function [23]; figure copying from the CERAD constructional praxis exercise to assess visuospatial skills on a scale from zero to 11, with higher scores indicating better functioning [23]; a 15-word short version of the Boston Naming Test (BNT) [24] to assess word retrieval; the animal-naming test to assess semantic fluency [25]; and the controlled oral word association test (COWAT-FAS test) to assess phonemic fluency [26].

The Clinical Dementia Rating scale (CDR) was used as a global measure of dementia. The scale includes six items that assess cognition and activities of daily living (memory,
orientation, judgment and problem solving, community affairs, home and hobbies, and personal care). Each item on the CDR can be scored as zero, 0.5, 1, 2, or 3; the higher the score, the more severe the impairment. The subscores can be added, yielding a sum score between zero and 18 points—the CDR Sum of Boxes (CDR-SB) [27]. In addition to the sum score, a total CDR score can be calculated using an algorithm that gives priority to the memory item, reflecting the stage of dementia: 0 (no dementia), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate dementia), or 3 (severe dementia). The CDR was scored by the same CDR-certified co-authors (KP, RSE, or MLB) at baseline and follow-up, based on all available clinical data. The raters were blinded to the baseline CDR score when assessing CDR at follow-up and vice versa. The progression rate was calculated as the annual change in CDR-SB.

To assess depressive symptoms during the previous week, the Cornell Scale for Depression in Dementia (CSDD), comprising 19 items with possible scores from zero to 2, was administered. The maximum sum score is 38 points; the higher the score, the more severe the depressive symptoms are [28]. To assess neuropsychiatric symptoms, the Neuropsychiatric Inventory Questionnaire (NPI-Q), a 12-item informant scale, was administered [29]. NPI-Q rates the severity of neuropsychiatric symptoms on a scale from zero to 3, for a total score of zero to 36; the higher the score, the more severe the neuropsychiatric symptoms are.

Data on previous cerebrovascular disease and risk factors were registered from the patients’ records.

Magnetic resonance imaging

The MRI examinations had been conducted at different locations with somewhat different protocols but all with coronal, transverse and sagittal imaging, in 63 of the cases with 3DT1 and T2 sequence in the other 60 patients. Field strength (1.5 T or 3 T) also differed. The distribution of scans with or without 3DT1 and 1.5 or 3 T did not differ between the subtypes (Table 1). A neuroradiologist (LC) with extensive experience evaluating cerebral atrophy using rating scales examined the MRI scans blinded to any clinical data [30, 31]. Medial temporal lobe atrophy (MTA) was assessed in both hemispheres using the Scheltens scale, including evaluation of the choroidal fissure, the temporal horn of the lateral ventricles, and the height of the hippocampus on a scale from zero to four [32]; the higher the score, the more atrophy is present. A mean of the two hemisphere scores was calculated. Frontal atrophy was assessed using the global cortical atrophy frontal subscale (GCA-f) [33, 34], evaluating the width of the sulci and the volume of the gyri in the frontal lobes on a scale from zero to three; the higher the score, the greater the amount of atrophy. Posterior atrophy was assessed using the Koedam scale (PA), including evaluation of the posterior cingulate, the parieto-occipital sulcus, the precuneus, and the widening of sulci and volume of gyri in the parietal lobes, on a scale from zero to three; the higher the score, the greater the atrophy [35]. The neuroradiologist has demonstrated excellent intrarater agreement for the MTA scale and substantial agreement for the other two scales in previous studies [30, 31].

Recently developed age-adjusted cut-offs [31] were used to evaluate whether atrophy was present in the three separate brain regions and to categorize the patients according to atrophy-pattern subtypes [11]. This subdivision is illustrated in Fig 1. If both the MTA and one or both of the other scales were abnormal, the atrophy pattern was regarded as typical AD. If only the MTA was abnormal, the pattern was regarded as limbic-predominant. If the MTA was normal, and one or both of the other scales were abnormal, the pattern was regarded as hippocampal-sparing. In addition, if all three scales were normal, the pattern was regarded as minimal-atrophy.
### Table 1. Baseline characteristics of the patients by AD subtype based on age-adjusted visual rating scale measures of the atrophy in the medial temporal lobes (Scheltens MTA scale), frontal lobes (GCA-4) and posterior regions (Koedams scale).

|                          | Minimal-atrophy | Limbic-predominant | Hippocampal-sparing | Typical AD n = 59, 48.0% | p*  | p**   |
|--------------------------|-----------------|--------------------|---------------------|--------------------------|-----|-------|
| Age, years (SD)          | 73.4 (7.5)      | 75.1 (6.2)         | 71.4 (9.9)          | 74.3 (6.7)               | 0.620 | 0.735 |
| Female gender, %         | 68.8%           | 58.6%              | 47.4%               | 54.2%                    | 0.298 | 0.274 |
| Education, years (SD; range) | 9.4 (3.1; 7–18) | 11.4 (3.1; 7–18)  | 11.7 (4.2; 7–20)   | 11.9 (3.6; 7–20)         | 0.013 | 0.014 |
| 0–7 years, n (%)         | 7 (43.8)        | 4 (13.8)           | 3 (15.8)            | 5 (8.5)                  | 0.001 | 0.001 |
| 8–13 years, n (%)        | 7 (43.8)        | 19 (65.5)          | 10 (52.6)           | 36 (61.0)                | 0.216 | 0.198 |
| >13 years, n (%)         | 2 (12.5)        | 6 (20.7)           | 6 (31.6)            | 18 (30.5)                | 0.149 | 0.186 |
| Symptom duration, years (SD) | 2.7 (2.3)      | 2.9 (2.0)          | 3.9 (2.7)           | 3.2 (2.4)                | 0.494 | 0.417 |
| Age at onset*            | 70.7 (8.3)      | 72.2 (6.8)         | 68.4 (11.1)         | 71.4 (7.2)               | 0.741 | 0.844 |
| Mean follow-up time, months (SD) | 22.7 (2.8) | 23.0 (3.4)        | 25.0 (3.5)          | 23.5 (2.7)               | 0.306 | 0.265 |
| MMSE                     | 20.7 (4.6)      | 22.1 (4.7)         | 22.8 (4.8)          | 22.3 (3.9)               | 0.170 | 0.157 |
| Clock drawing test       | 3.6 (1.5)       | 3.5 (1.6)          | 3.0 (1.6)           | 3.1 (1.7)                | 0.298 | 0.378 |
| TMT A below 180 sec, n (%) | 16 (100)       | 19 (73.1)          | 17 (89.5)           | 47 (82.5)                | 0.071 | 0.059 |
| TMT B below 360 sec, n (%) | 3 (23.1)      | 12 (57.1)          | 6 (33.3)            | 25 (45.5)                | 0.140 | 0.122 |
| Delayed recall           | 1.6 (1.8)       | 1.6 (2.2)          | 1.9 (2.0)           | 0.9 (1.3)                | 0.180 | 0.446 |
| Figure copying           | 8.8 (2.4)       | 10.9 (0.4)         | 9.0 (2.2)           | 8.7 (2.7)                | 0.917 | 0.791 |
| Boston naming test       | 9.3 (3.6)       | 9.9 (3.9)          | 10.6 (2.6)          | 10.3 (3.0)               | 0.284 | 0.294 |
| Animal naming            | 9.8 (4.9)       | 11.8 (5.7)         | 12.4 (6.1)          | 10.7 (5.3)               | 0.649 | 0.465 |
| Phonemic fluency         | 31.0 (13.1)     | 31.7 (11.5)        | 29.6 (14.5)         | 28.6 (15.4)              | 0.746 | 0.804 |
| Cornell sum              | 5.6 (4.6)       | 5.5 (4.7)          | 6.7 (6.4)           | 5.0 (4.2)                | 0.617 | 0.896 |
| NPI-Q delusions, n/total reg (%) | 2/15 (13) | 7/26 (27)          | 3/18 (17)           | 11/57 (19)               | 0.593 | 0.499 |
| NPI-Q hallucinations, n/total reg (%) | 0/15        | 2/26 (8)        | 5/18 (11)           | 3/57 (5)                 | 0.364 | 0.293 |
| Cerebral stroke/TIAb, n (%) | 3/15 (20)   | 13/26 (50)         | 7/17 (41)           | 13/57 (23)               | 0.816 | 0.311 |
| Hypertension, n (%)      | 5 (31)          | 13 (45)            | 7 (37)              | 28 (48)                  | 0.247 | 0.305 |
| Diabetes mellitus, n (%) | 2 (13)          | 5 (17)             | 1 (5)               | 3 (5)                    | 0.292 | 0.593 |
| 3DT1 sequence, n (%)     | 8 (50)          | 9 (31)             | 33 (24)             | 0.672                    | 0.917 | 0.917 |
| NPI-Q sleep, n/total reg (%) | 6 (38)       | 14 (48)            | 6 (32)              | 26 (44)                  | 0.638 | 0.678 |
| CDR-SB baseline          | 4.3 (1.0)       | 4.9 (1.8)          | 4.7 (1.8)           | 5.4 (1.6)                | 0.002 | 0.010 |
| CDR-memory               | 0.97 (0.13)     | 1.07 (0.35)        | 1.21 (0.51)         | 1.24 (0.46)              | <0.001 | <0.001 |
| CDR-orientation          | 0.81 (0.31)     | 0.91 (0.40)        | 0.89 (0.49)         | 1.01 (0.43)              | 0.093 | 0.184 |
| CDR-judgment             | 0.84 (0.24)     | 0.81 (0.36)        | 0.84 (0.29)         | 0.91 (0.25)              | 0.376 | 0.743 |
| CDR-social               | 0.63 (0.22)     | 0.78 (0.37)        | 0.76 (0.42)         | 0.91 (0.44)              | 0.016 | 0.003 |
| CDR-hobbies              | 0.78 (0.26)     | 1.03 (0.58)        | 0.89 (0.54)         | 1.02 (0.45)              | 0.051 | 0.092 |
| CDR-personal care        | 0.31 (0.48)     | 0.34 (0.48)        | 0.21 (0.42)         | 0.34 (0.51)              | 0.853 | 0.968 |
| CDR score baseline       | 0.7 (0.3)       | 0.8 (0.2)          | 0.8 (0.2)           | 0.9 (0.2)                | 0.023 | 0.024 |
| APOE-ε 4 carrier, %      | 56.3%           | 66.7%              | 72.2%               | 64.8%                    | 0.533 | 0.417 |
| Amyloid β, ng/L          | 681 (290)       | 438 (193)          | 534 (143)           | 502 (158)                | 0.028 | 0.007 |
| Amyloid β, % abnormalc   | 22.2            | 81.3               | 40.0                | 64.0                     | 0.031 | 0.017 |
| Total tau, ng/L          | 768 (437)       | 701 (383)          | 891 (319)           | 615 (267)                | 0.225 | 0.566 |
| Total tau, % abnormalc   | 66.7%           | 62.5%              | 90.0%               | 64.0%                    | 0.886 | 0.907 |
| Phosphorylated tau, ng/L | 95 (46)         | 84 (34)            | 112 (38)            | 81 (31)                  | 0.315 | 0.604 |

(Continued)
Other assessments

APOE genotyping was conducted using the Illumina Infinium OmniExpress v1.1 chip at deCODE Genetics, Reykjavik, Iceland, and the results were dichotomized based on APOE-ε4 status (carrier of at least one APOE-ε4 allele, or not).

Lumbar puncture with measures of AD biomarkers (amyloid-β [Aβ], phosphorylated tau [P-tau] and total tau [T-tau]) in the cerebrospinal fluid (CSF) was carried out in 60 of the 123 patients. The CSF examination was done in patients where more information was warranted to increase the etiological diagnostic precision, mostly in younger patients. All CSF samples were analyzed at Akershus University Hospital (AHUS) using ELISA technique with the Innotest kit (Innogenetics, Ghent, Belgium). As the analyses were carried out as part of the clinical routine, the samples were analyzed on different dates and with different batches. The laboratory is part of the Alzheimer’s Association quality-control program for CSF biomarkers through a collaboration with the Clinical Neurochemistry Laboratory in Gothenburg, Sweden.
Cut-offs developed at AHUS were used when dichotomizing the results into a pathological/nonpathological variable (normal references: Aβ 550–1200 ng/L, P-tau <80 ng/L, T-tau in patients with ages <50, <300 ng/L; in patients 50–70 years, <450 ng/L; in patients with ages >70, <500 ng/L).

**Statistical analysis**

The data were analyzed using IBM SPSS Statistics for Windows, version 22.0, Armonk, NY, USA. Demographic and clinical characteristics across subtypes were compared using Student’s t-test and ANOVA for continuous data and with χ²-test for categorical data. Logistic regression analyses were performed to further explore differences found in the comparisons between the minimal-atrophy group and typical AD (total n = 74) and between the minimal-atrophy AD group and all other AD subtypes (total n = 122). A p-value below 0.05 was used as a threshold for statistical significance.

**Ethics**

The patients and caregivers received oral and written information and gave written consent to participate. Only patients with the capacity to consent were recruited at baseline. Caregivers gave written consent if the patient lacked the capacity to consent at follow-up.

The Regional Committees for Ethics in Medical Research in South-Eastern Norway approved the study (REK 2011/531).

**Results**

The mean age of the patients was 74.0 (SD 7.3) years; 56% were females; the mean MMSE was 22.1 (SD 4.3); mean formal education was 11.4 (SD 3.6) years; and the mean annual progression as measured by the CDR-SB change was 2.2 (SD 2.0) for all 123 patients.

Table 1 shows the four atrophy-pattern AD subtypes identified through the MRI visual rating scales, with descriptive data: 59 (48%) patients had typical AD; 29 (24%) had limbic-predominant AD; 19 (15%) had hippocampal-sparing AD; and 16 (13%) had the minimal-atrophy AD pattern. No differences regarding demographic, cognitive, APOE-ε4, CSF biomarkers, neuropsychiatric symptoms, cerebrovascular comorbidity and risk factors, or progression rate (see also Fig 2) were identified among the four subtypes using ANOVA (not shown). Comparing the minimal-atrophy group with typical AD and all other AD subtypes showed that the number of years of education and CDR-SB score at baseline were lower in the minimal-atrophy group, and the level of Aβ was higher (as was the percentage of patients in the minimal-atrophy group with Aβ levels above the cut-off, i.e., a negative test result). No other differences were found between these groups (Tables 1 and 2).

Tables 3 and 4 show the results from the logistic regression analyses comparing the minimal-atrophy group with typical AD and all other AD subtypes, respectively. As can be seen, patients in the minimal-atrophy group had significantly fewer years of formal education and lower CDR-SB at baseline in the adjusted models (models 1, 2 and 3). The score on the MMSE, by contrast, did not differ between the groups, either in unadjusted or adjusted analyses.

In total, 60 patients had available CSF biomarkers, of which nine patients belonged to the minimal-atrophy group. When Aβ level was added to model 3 in Table 4 (minimal-atrophy versus all other AD subtypes, n = 59), the Aβ level was, in addition to education and CDR-SB, a significant variable (p 0.038), with higher levels of Aβ in the minimal-atrophy group (data not shown).
Discussion

Previous neuroimaging studies have identified three subtypes of AD found to correlate well with neuropathological findings of neurofibrillary tangle distribution [6, 9, 12, 37]. In the extension of these findings, a fourth subtype showing no atrophy or minimal atrophy on MRI has recently been recognized [10, 11]. The first aim of the present study was to explore whether the same four subtypes, identified using MRI assessed with three different visual rating scales,

Fig 2. Progression as measured by the CDR-SB at baseline and follow-up.
https://doi.org/10.1371/journal.pone.0186595.g002

Table 2. Follow-up characteristics of the patients by AD subtype.

|                          | Minimal-atrophy n = 16, 13.0% | Limbic-predominant n = 29, 23.6% | Hippocampal-sparing n = 19, 15.4% | Typical AD n = 59, 48.0% | p* | p** |
|--------------------------|-------------------------------|---------------------------------|---------------------------------|--------------------------|----|-----|
| MMSE follow-up           | 17.9 (7.1)                    | 20.0 (5.0)                      | 19.0 (4.5)                      | 16.8 (7.0)               | 0.587 | 0.965 |
| MMSE annual change       | -1.3 (2.4)                    | -1.6 (2.2)                      | -1.7 (2.1)                      | -2.8 (3.0)               | 0.093 | 0.209 |
| Delayed recall follow-up| 0.7 (1.4)                     | 0.5 (0.8)                       | 1.4 (2.1)                       | 0.3 (0.6)                | 0.316 | 0.572 |
| Delayed recall annual change | -0.50 (0.98)            | -0.53 (0.84)                    | 0.02 (0.79)                     | -0.23 (0.55)             | 0.304 | 0.249 |
| Phonemic fluency follow-up | 22.1 (14.1)                  | 22.9 (10.8)                     | 25.8 (15.5)                     | 17.9 (15.9)              | 0.371 | 0.700 |
| Phonemic fluency annual change | -4.6 (6.9)                   | -5.3 (3.1)                      | -0.7 (3.7)                      | -2.7 (6.3)               | 0.567 | 0.510 |
| CDR-SB follow-up         | 9.1 (3.4)                     | 8.4 (4.1)                       | 9.4 (4.4)                       | 9.5 (3.7)                | 0.662 | 0.887 |
| CDR-SB annual change     | 2.5 (1.9)                     | 1.9 (2.2)                       | 2.3 (2.2)                       | 2.1 (2.0)                | 0.512 | 0.472 |
| CDR score follow-up      | 1.5 (0.5)                     | 1.3 (0.7)                       | 1.6 (0.8)                       | 1.6 (0.7)                | 0.663 | 0.921 |
| CDR score annual change  | 0.41 (0.30)                   | 0.29 (0.39)                     | 0.36 (0.38)                     | 0.36 (0.40)              | 0.662 | 0.524 |

All measures reported as mean (SD). “Annual change” calculated as change between follow-up assessment (17–34 months) and baseline assessment, per year.

*Minimal-atrophy—Typical AD, t-test.
** Minimal-atrophy—All other AD subtypes, t-test.
MMSE Mini-mental State Examination, CDR-SB Clinical Dementia Rating scale sum of boxes.

https://doi.org/10.1371/journal.pone.0186595.t002
would exist in a heterogeneous naturalistic memory-clinic sample, as has been found in two previous studies carried out in the more selective ADNI cohorts [13]. The prevalence of the subtypes identified in the present study was in line with previous findings, with typical AD being the most frequent subtype, occurring in 48% of the patients in the present study compared to 38–59% in previous studies, followed by the limbic-predominant and hippocampal-sparing AD subtypes, occurring in 24% and 15% respectively in the present study compared to 17–29% and 12–18% in previous studies. Finally, the minimal-atrophy subtype represented 13% of the patients, as compared to 10–17% in previous studies [10, 11].

When comparing the minimal-atrophy group to both typical AD and all other AD subtypes, no differences were found with regard to cognitive function. The two previous studies on MRI subtypes of AD found a lower MMSE score in the minimal-atrophy group, but Ferreira et al. concluded that, based on a broader cognitive test battery, there was great overlap between the subtypes [10, 11]. Moreover, in the present study, no significant difference in the progression rate could be found. The only observed differences were that the minimal-atrophy group had significantly fewer years of formal education, a tendency that was also reported in previous studies [10, 11]; in addition, they had a lower CDR-SB score at baseline, and fewer patients had pathological levels of Aβ. These differences remained significant in adjusted analyses.

While the lack of or lower degree of atrophy and higher Aβ level could indicate that the minimal-atrophy AD subtype had been misdiagnosed as AD, we believe that the similar cognitive deficits and progression rate in this group, as compared to the other subtypes, do indicate that, clinically, these patients had AD. In addition, they clearly fulfilled the diagnostic criteria

### Table 3. Logistic regression. Minimal-atrophy (0)-Typical AD (1).

|          | n = 74 | Unadjusted | Model 1 | Model 2 | Model 3 |
|----------|--------|------------|---------|---------|---------|
|          |        | OR (95% CI) | p       | OR (95% CI) | P       | OR (95% CI) | p       | OR (95% CI) | p       |
| Age      |        | 1.02 (0.94; 1.11) | 0.570 | 1.04 (0.95–1.13) | 0.401 | 1.04 (0.95–1.13) | 0.425 | 1.01 (0.92–1.12) | 0.766 |
| Female   |        | 0.522 (0.16; 1.69) | 0.279 | 0.85 (0.24–3.04) | 0.797 | 0.85 (0.24–3.05) | 0.801 | 1.52 (0.35–6.56) | 0.575 |
| Education|        | 1.32 (1.05–1.65) | 0.016 | 1.33 (1.05–1.68) | 0.018 | 1.31 (1.03–1.68) | 0.028 | 1.46 (1.12–1.89) | 0.005 |
| MMSE     |        | 1.10 (0.96; 1.25) | 0.175 | 1.02 (0.89–1.18) | 0.769 |             |       |             |       |
| CDR-SB   |        | 1.76 (1.08; 2.87) | 0.023 |             |       | 2.17 (1.22–3.87) | 0.009 |             |       |
| Nagelkerke|       | 17.2        |       | 17.4        |       | 34.3        |       |             |       |

MMSE Mini-mental State Examination, CDR-SB Clinical Dementia Rating scale sum of boxes. In the unadjusted column, only one variable was included at a time. For model 1, 2 and 3, the variables with presented data were added simultaneously.

https://doi.org/10.1371/journal.pone.0186595.t003

### Table 4. Logistic regression. Minimal-atrophy (0)-All other AD subtypes (1).

|          | n = 122 | Unadjusted | Model 1 | Model 2 | Model 3 |
|----------|---------|------------|---------|---------|---------|
|          |         | OR (95% CI) | p       | OR (95% CI) | P       | OR (95% CI) | p       | OR (95% CI) | p       |
| Age      |         | 1.01 (0.94; 1.09) | 0.708 | 1.04 (0.96–1.13) | 0.367 | 1.04 (0.96–1.13) | 0.380 | 1.03 (0.94–1.11) | 0.565 |
| Female   |         | 0.53 (0.17; 1.63) | 0.266 | 0.74 (0.23–2.37) | 0.609 | 0.75 (0.23–2.45) | 0.637 | 0.80 (0.24–2.71) | 0.719 |
| Education|         | 1.29 (1.05; 1.60) | 0.017 | 1.31 (1.05–1.64) | 0.018 | 1.30 (1.03–1.64) | 0.031 | 1.43 (1.11–1.84) | 0.005 |
| MMSE     |         | 1.09 (0.97; 1.22) | 0.161 | 1.02 (0.90–1.15) | 0.807 |             |       |             |       |
| CDR-SB   |         | 1.38 (0.97; 1.97) | 0.075 |             |       | 1.68 (1.11–2.55) | 0.014 |             |       |
| Nagelkerke|        | 12.8        |       | 12.8        |       | 22.4        |       |             |       |

MMSE Mini-mental State Examination, CDR-SB Clinical Dementia Rating scale sum of boxes. In the unadjusted column, only one variable was included at a time. For model 1, 2 and 3, the variables with presented data were added simultaneously.

https://doi.org/10.1371/journal.pone.0186595.t004
for AD [16, 17]. However, there is also a possibility that the minimal-atrophy group could represent other dementia disorders, for instance, dementia with Lewy bodies [38], but as the clinical symptomatology, progression rate, behavioral symptoms like hallucinations and delusions, and degree of cerebrovascular comorbidity or cerebrovascular risk factors were similar compared to the other AD patients, this is unlikely [39].

The question remains unanswered regarding whether the CSF Aβ is false negative, another pathological substrate is actually present in this patient group, or it could be negative because the minimal-atrophy group is at an earlier neuropathological stage.

In summary, we suggest that fewer years of formal education, the lack of MRI-assessed atrophy, and the smaller number of patients with pathological Aβ levels but clinical AD phenotype are findings that could be in line with the cognitive reserve hypothesis (CRH) [40].

The CRH proposes that education is beneficial for the brain, both by producing more efficient and pathology-robust brain networks (neural reserve) and by neural compensation, in which well-developed brain networks can be used in new and unusual ways when the brain is damaged by disease or injury [40]. Furthermore, in patients with similar degrees of cognitive impairment, the underlying pathology of AD has been demonstrated to be more advanced in highly educated patients, while patients with less education show less pathological alteration [40]. We believe that the results of the present study could be in line with this hypothesis. Patients with less education develop symptoms earlier in the neuropathological disease progression when tangles start to form and neurons malfunction and die, even before atrophy can be identified on MRI.

The results of the present study align with other studies that have reported thinner regional cortices or more regional atrophy [41–45] and reduced white matter fiber tract integrity [46] in highly educated AD patients compared to equally impaired patients with less education. Furthermore, similar tendencies related to fewer years of formal education in the minimal-atrophy AD subtype were reported in the studies by Byun et al. and Ferreira et al. [10, 11]. We have found only one study that reported findings in contrast with this. Shpanskaya et al. found a positive association between education and hippocampal volume in AD [47]. However, they did not adjust for disease duration or cognitive function. Adding APOE-ε4 status to our models, as done by Shpanskaya et al., did not change our results.

As previously noted, we found that the levels of Aβ and the number of patients with negative Aβ results according to cut-offs were higher in the minimal-atrophy group compared to patients of the other subtypes. Bennett et al. concluded that education modifies the relationship of amyloid to cognition, meaning that patients with less education need less amyloid pathology to develop cognitive symptoms [48, 49]. Although our result regarding the minimal-atrophy group having higher Aβ levels could be in line with the CRH, it is in contrast to previous studies reporting equally or even greater pathological levels of Aβ in the minimal-atrophy group [10, 11]. There might be several reasons for this discrepancy. One possible explanation is that, in all the studies, the proportion of patients with CSF biomarkers was between 49% and 67%, which could create selection bias in different ways depending on how patients were selected for CSF analysis.

Concerning the other CSF biomarkers, the minimal-atrophy group had levels of t-tau and p-tau similar to the other groups. Earlier research conducted with mice has found t-tau and p-tau to be secreted from neurons possibly stimulated by Alzheimer-related factors, e.g., amyloid [50]. We further suggest that in humans, these CSF markers therefore do not have to reflect neurodegeneration and tangle pathology directly, and the finding of these patients having high t-tau and p-tau is thus not in contrast to the hypothesis that they have little tangle pathology.

Another discrepancy between the present and two previous longitudinal studies is that, whereas Byun et al. and Ferreira et al. [10, 11] found that the minimal-atrophy group had the
slowest progression rate among the groups, we did not find such a difference. In addition, both studies were based on the same selective research cohort (ADNI) and not on a heterogeneous sample of clinical patients, as our memory-clinic cohort was (our cohort possibly including more vascular comorbidity). For these reasons, the studies were not entirely comparable.

One last finding that needs discussion was that the less-educated, minimal-atrophy group had similar test results as the other subtypes regarding the MMSE and other cognitive tests at baseline, while the global score as measured with the CDR-SB (memory and social items more specifically) was lower (indicating better function). This could seem contradictory, but as the CDR should not only reflect cognitive test results but also the functional level as reported by a proxy, we suggest this result indicates that this patient group better maintains well-incorporated overall daily functioning compared to specific cognitive functions. However, as the CDR-SB remains significant after correcting for educational level and substantially increases the explained variance, educational level/CRH does not explain all the difference in CDR-SB between the groups. Possibly, the proxy information is the relevant factor creating this difference, or the atrophy subtype has a more direct impact on cognition and less impact on, or better preservation of, function.

During the last decade, several international working groups have proposed newer ways of diagnosing AD, incorporating knowledge of its neurobiology and the use of biomarkers at different levels of necessity [1, 51]. The finding of less-educated patients with AD lacking cerebral atrophy is important, as these patients, according to several of the suggested criteria, would not receive an AD diagnosis. The results of the present study could also imply that visual rating scales might not be sensitive enough to capture low degrees of atrophy; however, both Ferreira et al. and Byun et al., using automated MRI methods, confirmed the lack of atrophy in the minimal-atrophy group [10, 11].

There are limitations to this study. The risk of the minimal-atrophy group being misdiagnosed as AD has been discussed but is regarded unlikely because their cognitive profiles and progression rates are similar to those of other patients, as well as the fact that they were diagnosed by experienced physicians based on a broad clinical assessment and according to standardized diagnostic criteria. The patients were rediagnosed at follow-up, and all except two retained an AD diagnosis (one with limbic-predominant and one with typical AD pattern). In addition, potential differential diagnoses such as depression and atrophy in other parts of the brain have been regarded in the previous studies. Neither the present study nor the study by Byun et al. found any differences regarding depression [10], and atrophy in other parts of the brain has not been found to differ between the subtypes either [10].

MRI imaging was conducted using different MRI protocols, which might reduce reliability. To reduce variability, only one neuroradiologist performed the visual ratings. The neuroradiologist was used to image heterogeneity through extensive practice in the use of visual rating scales in both clinical routine and research settings [30, 31]. With regard to the T1/T2 contrast and field strength heterogeneity, the distribution was not significantly different among the AD subtypes. While T1/T2 might affect atrophy ratings, a situation that the neuroradiologist is accustomed to and takes into account during ratings, field strength is not found to affect atrophy ratings [52]. Another MRI-related limitation was that the cut-offs used were based on only a single study, however, the cut-offs have been validated in several later studies [53, 54].

The number of patients with available CSF analysis was low, and the risk of selection bias is present. Moreover, CSF samples were not analyzed on the same date with the same batches which might increase variability [55]. Therefore, the CSF results should be interpreted with caution.
Lastly, the number of patients, especially in the minimal-atrophy group, was low. However, similar prevalences as identified in previous studies were found, thereby strengthening the results.

Future studies are needed to test whether the current findings can be replicated. We suggest that adding more measures of cognitive reserve, such as previous and current occupation or measures of intelligence or literacy, would strengthen a future study [56].

**Conclusion**

Previous results concerning the prevalence and the similar phenotypic expressions of the four AD subtypes were confirmed. In this clinical sample, no differences in progression rates were found. The main finding was that patients without evident atrophy, as assessed by three visual MRI rating scales, had less education than other patients. We believe this finding may support the cognitive reserve hypothesis. Patients with higher education can cope with more neuropathological changes than less-educated patients can, or put another way, patients with less formal education might present with clinically typical AD symptoms before they have positive biomarkers of AD. This finding represents a challenge that should be considered in the process of developing new diagnostic criteria in order not to lose sensitivity, and it should be kept in mind by physicians examining patients with fewer years of formal education as well as in relation to treatment trials.

**Acknowledgments**

We want to acknowledge the Norwegian registry for persons being evaluated for cognitive symptoms in specialized care (NorCog) by the Norwegian National Advisory Unit on Ageing and Health, for contributing with patient data.

**Author Contributions**

**Conceptualization:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Daniel Ferreira, Anne-Brita Knapskog, Geir Selbæk, Anne Brækhus, Ingvild Saltvedt, Eric Westman, Knut Engedal.

**Data curation:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca.

**Formal analysis:** Karin Persson, Daniel Ferreira, Eric Westman, Knut Engedal.

**Funding acquisition:** Ingvild Saltvedt, Knut Engedal.

**Investigation:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Lena Cavallin, Daniel Ferreira, Anne-Brita Knapskog, Anne Brækhus, Knut Engedal.

**Methodology:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Lena Cavallin, Daniel Ferreira, Anne-Brita Knapskog, Geir Selbæk, Ingvild Saltvedt, Eric Westman, Knut Engedal.

**Project administration:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Geir Selbæk, Ingvild Saltvedt, Knut Engedal.

**Resources:** Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Lena Cavallin, Anne-Brita Knapskog.

**Supervision:** Geir Selbæk, Anne Brækhus, Knut Engedal.

**Writing – original draft:** Karin Persson, Daniel Ferreira, Knut Engedal.
Writing – review & editing: Karin Persson, Rannveig Sakshaug Eldholm, Maria Lage Barca, Lena Cavallin, Daniel Ferreira, Anne-Brita Knapskog, Geir Selbæk, Anne Brækhus, Ingvild Saltvedt, Eric Westman, Knut Engedal.

References

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005 PMID: 21514250

2. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010; 19:1401–8. https://doi.org/10.3233/JAD-2010-1337 PMID: 20661618

3. Dickerson BC, McGinnis SM, Xia C, Price BH, Atri A, Murray ME, et al. Approach to atypical Alzheimer’s disease and case studies of the major subtypes. CNS spectrums. 2017;1–11.

4. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011; 3:77sr1. https://doi.org/10.1126/scitranslmed.3002369 PMID: 21471435

5. Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol scand Suppl. 1996; 165:3–12. PMID: 8740983

6. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011; 10:785–96. https://doi.org/10.1016/S1474-4422(11)70156-9 PMID: 21802369

7. Whitwell JL, Josephs KA, Murray ME, Kantarcı K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008; 71:743–9. https://doi.org/10.1212/01.wnl.0000324924.91351.7d PMID: 18765650

8. Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004; 18:190–5. PMID: 15992129

9. Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol. 2012; 11:868–77. https://doi.org/10.1016/S1474-4422(12)70200-4 PMID: 22951070

10. Byun MS, Kim SE, Park J, Yi D, Choe YM, Sohn BK, et al. Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease. PLoS One. 2015; 10: e0142756. https://doi.org/10.1371/journal.pone.0142756 PMID: 26818360

11. Ferreira D, Verhagen C, Hernandez-Cabrera JA, Cavallin L, Guo CJ, Ekman U, et al. Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Sci Rep. 2017; 7:46263. https://doi.org/10.1038/srep46263 PMID: 28417965

12. Hwang J, Kim CM, Jeon S, Lee JM, Hong YJ, Roh JH, et al. Prediction of Alzheimer’s disease pathophysiology based on cortical thickness patterns. Alzheimer’s & dementia (Amsterdam, Netherlands). 2016; 2:58–67.

13. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005; 15:869–77. https://doi.org/10.1016/j.nic.2005.09.008 PMID: 16443497

14. Persson K, Barca M, Eldholm R, Cavallin L, Benth JS, Selbæk G, et al. Visual evaluation of medial temporal lobe atrophy as a clinical marker of conversion from MCI to dementia and for predicting progression in patients with MCI and mild AD. Dement Geriatr Cogn Disord. 2017.

15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159–74. PMID: 843571

16. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.

17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34:939–44. PMID: 6610841

18. Brækhus A, Ulstein I, Wyller TB, Engedal K. The Memory Clinic—outpatient assessment when dementia is suspected. Tidsskr Nor Laegeforen. 2011; 131:2254–7. https://doi.org/10.4045/tidsskr.11.0786 PMID: 22085955
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189–98. PMID: 1202204
20. Engedal K, Haugen P, Gilje K, Laake P. Efficacy of short mental tests in the detection of mental impairment in old age. Compr Gerontol A. 1988; 2:87–93. PMID: 3228822
21. Shulman KJ, Shedletsky R, Silver IL. The challenge of time: Clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry. 1986; 1:135–40.
22. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958; 8:271–6.
23. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989; 39:1159–65. PMID: 2771064
24. Kaplan E, Goodglass H, & Weintraub S. Boston naming test. Philadelphia: Lea & Febiger; 1983.
25. Goodglass H, Kaplan E. Assessment of aphasia and related disorders. Philadelphia: Lea & Febiger; 1972.
26. Benton A, Hamsher K, Sivan AB. Multilingual aphasia examination. Iowa City, IA: AJA; 1976.
27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140:566–72. PMID: 7104545
28. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988; 23:271–84. PMID: 3337862
29. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000; 12:233–9. https://doi.org/10.1176/jnp.12.2.233 PMID: 11001602
30. Cavallin L, Loken K, Engedal K, Oksengard AR, Wahlund LO, Bronge L, et al. Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiol. 2012; 53:318–23. https://doi.org/10.1258/ ar.2012.110552 PMID: 22371624
31. Ferreira D, Cavallin L, Larsson EM, Muehlboeck JS, Mecocci P, Vellas B, et al. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer’s disease and mild cognitive impairment. J Intern Med. 2015; 278:277–90. https://doi.org/10.1111/joim.12358 PMID: 25752192
32. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992; 55:967–72. PMID: 1431963
33. Pasquier F, Leys D, Weerts JG, Mounier-Ve hier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996; 36:268–72. PMID: 8864706
34. Ferreira D, Cavallin L, Granberg T, Lindberg O, Aguilar C, Mecocci P, et al. Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. Eur Radiol. 2016; 26:2597–610. https://doi.org/10.1007/s00330-015-4101-9 PMID: 26560730
35. Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011; 21:2618–25. https://doi. org/10.1007/s00330-011-2205-4 PMID: 21805370
36. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement. 2013; 9:251–61. https://doi.org/10.1016/j.jalz.2013.01.010 PMID: 23622690
37. Noh Y, Jeon S, Lee JM, Seo SW, Kim GH, Cho H, et al. Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. Neurology. 2014; 83:1936–44. https://doi.org/10.1212/WNL. 0000000000001003 PMID: 25344382
38. Barber R, Ballard C, McKeith IG, Ghoklar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology. 2000; 54:1304–9. PMID: 10746602
39. Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, et al. Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. J Alzheimers Dis. 2017; 57:787–95. https://doi.org/10.3233/JAD-161109 PMID: 28304294
40. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012; 11:1006–12. https://doi.org/10.1016/S1474-4422(12)70191-6 PMID: 23079557
41. Mondragon JD, Celada-Borja C, Barinagarrementeria-Aldatz F, Burgos-Jaramillo M, Barragan-Campos HM. Hippocampal Volumetry as a Biomarker for Dementia in People with Low Education. Dement Geriatr Cogn Dis Extra. 2016; 6:486–99. https://doi.org/10.1159/000449424 PMID: 27920792
42. Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, et al. Early diagnosis of Alzheimer’s disease using cortical thickness: impact of cognitive reserve. Brain. 2009; 132:2036–47. https://doi.org/10.1093/brain/awp105 PMID: 19439419

43. Seo SW, Im K, Lee JM, Kim ST, Ahn HJ, Go SM, et al. Effects of demographic factors on cortical thickness in Alzheimer’s disease. Neurobiol Aging. 2011; 32:200–9. https://doi.org/10.1016/j.neurobiolaging.2009.02.004 PMID: 19321233

44. Schweizer TA, Ware J, Fischer CE, Craik FI, Bialystok E. Bilingualism as a contributor to cognitive reserve: evidence from brain atrophy in Alzheimer’s disease. Cortex. 2012; 48:991–6. https://doi.org/10.1016/j.cortex.2011.04.009 PMID: 21596373

45. Liu Y, Julkunen V, Paajanen T, Westman E, Wahlund LO, Aitken A, et al. Education increases reserve against Alzheimer’s disease— evidence from structural MRI analysis. Neuroradiology. 2012; 54:929–38. https://doi.org/10.1007/s00234-012-1005-0 PMID: 22485697

46. Teipel SJ, Meindl T, Wagner M, Kohl T, Burger K, Reiser MF, et al. White matter microstructure in relation to education in aging and Alzheimer’s disease. J Alzheimers Dis. 2009; 17:571–83. https://doi.org/10.3233/JAD-2009-1077 PMID: 19433891

47. Shpanskaia KS, Choudhury KR, Hostage C Jr, Murphy KR, Petrella JR, Doraiswamy PM. Educational attainment and hippocampal atrophy in the Alzheimer’s disease neuroimaging initiative cohort. J Neurol. 2014; 41:350–7. https://doi.org/10.1016/j.jneurol.2013.11.004 PMID: 24485646

48. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Education modifies the association of amyloid but not tangles with cognitive function. Neurology. 2005; 65:953–5. https://doi.org/10.1212/01.wnl.0000176286.17192.69 PMID: 16186546

49. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology. 2003; 60:1909–15. PMID: 12821732

50. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013; 5:194re2. https://doi.org/10.1126/scitranslmed.3006446 PMID: 23863834

51. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gameau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010; 9:1118–27. https://doi.org/10.1016/S1474-4422(10)70223-4 PMID: 20934914

52. Guo H, Song X, Vandorpe R, Zhang Y, Chen W, Zhang N, et al. Evaluation of common structural brain changes in aging and Alzheimer disease with the use of an MRI-based brain atrophy and lesion index: a comparison between T1WI and T2WI at 1.5T and 3T. AJNR Am J Neuroradiol. 2014; 35:504–12. https://doi.org/10.3174/ajnr.A3709 PMID: 23988753

53. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, et al. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front Aging Neurosci. 2017; 9:117. https://doi.org/10.3389/fnagi.2017.00117 PMID: 28536518

54. Claus JJ, Staekenborg SS, Holt DC, Roorda JJ, Schuur J, Koster P, et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population. 2017; 27:3147–55.

55. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2015; 11:58–69. https://doi.org/10.1016/j.jalz.2014.02.004 PMID: 2479085

56. Manly JJ, Touradji P, Tang MX, Stern Y. Literacy and memory decline among ethnically diverse elders. J Clin Exp Neuropsychol. 2003; 25:680–90. https://doi.org/10.1076/jcen.25.5.680.14579 PMID: 12815505